

ChromaDex® Reports Financial Results for the Third Quarter 2012

2012-11-08

IRVINE, Calif. , Nov. 8, 2012 /PRNewswire/ --ChromaDex® Corporation (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, and marketer of its branded, patented pterostilbene, pTeroPure®, announced today financial results for the third quarter ended September 29, 2012 .

(Logo: <http://photos.prnewswire.com/prnh/20110830/LA59283LOGO>)

For the three months ended September 29, 2012 , ChromaDex reported record revenue of \$3,632,244 , an increase of 99% as compared to \$1,827,568 for the same period in 2011. The increase in sales is largely due to an increase in sales of the Company's **BluScience™** line of dietary supplements. The net loss attributable to common stockholders for the quarter ended September 29, 2012 was \$1,538,034 , or (\$0.02) per share as compared to a net loss of \$2,404,912 , or (\$0.03) per share for the same period in 2011. The non-cash, share-based compensation expense related to stock options and other share-based compensation for the third quarter of 2012 was \$925,393 . Excluding non-cash, share-based compensation expense, which is a "non-GAAP measure," would have the effect of decreasing the Company's net loss for the third quarter of 2012 to \$612,641 . As of September 29, 2012 , cash, cash equivalents and marketable securities totaled approximately \$1.2 million and inventories totaled approximately \$5.4 million .

Third quarter highlights include:

- In September, the Company's nutritional ingredient **pTeroPure** (pterostilbene) was highlighted at the American Heart Association's High Blood Pressure Research 2012 Scientific Sessions by investigators from the University of Mississippi Medical Center . The findings showed that, in a Phase 2/3 clinical trial, the ingredient showed statistically significant results for blood pressure in adults.
- In July, the Company announced a distribution agreement for pTeroPure with **Glanbia Nutritional (NA), Inc.** , a global ingredient and micronutrient premix company, whereby Glanbia will serve as the exclusive distributor of pTeroPure in North America to the food, beverage and dietary supplement industries.
- In July, the Company licensed from Dartmouth College exclusive rights to several patents related to the recently discovered vitamin found in milk, **Nicotinamide Riboside** (NR). The licensed intellectual property (IP) includes protection for human uses of NR as well as methods to produce NR. This license, coupled with previous IP rights for NR acquired from Cornell University , helps position ChromaDex as a leader in the commercialization of this novel 'no flush' version of niacin.

"The developments we saw transpire in the third quarter, including the acquisition of what we believe is the most relevant and valuable IP pertaining to the commercialization of NR, may prove to be one of the best opportunities

yet for ChromaDex to create shareholder value," said Frank Jaksch, Jr. , CEO and co-founder of ChromaDex.

"On the heels of the positive clinical results for pTeroPure, we recently began a public relations and media tour to educate trade and consumers on its multiple health benefits. Moreover, with the presentation of the clinical results, we have initiated various discussions with respect to potential licensing and partnering opportunities for pTeroPure."

Mr. Jaksch concluded, "We continue to execute on our unique business strategy of identifying novel ingredient technologies, securing intellectual property rights, developing commercially viable production processes, validating with clinical proof, and most importantly, executing on a commercialization and licensing strategy. Lastly, the pipeline of potential novel ingredient technologies remains active, and we anticipate being able to add to our current portfolio in the fourth quarter."

About ChromaDex®:

ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products includes patented pTeroPure® pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. The company has also launched ProC3G™, a natural black rice extract containing 40% cyanidin-3-glucoside and is in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property. For more information about pTeroPure, visit www.pteropure.com or call 949-600-9694.

Forward-Looking Statements:

Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

ChromaDex Investor Contact:

The Del Mar Consulting Group, Inc.
Robert B. Prag , President
858-794-9500
bprag@delmarconsulting.com

or

Alex Partners, LLC

Scott Wilfong , President
 425-242-0891
 Scott@alexpartnersllc.com

ChromaDex Contact:

Laura Carney , Executive Assistant
 949-419-0288
 laurac@chromadex.com

ChromaDex Corporation and Subsidiaries

Condensed Consolidated Statements of Operations (Unaudited)
 For the Three Month Periods Ended September 29, 2012 and October 1, 2011

	September 29, 2012	October 1, 2011
Sales	\$ 3,632,244	\$ 1,827,568
Cost of sales	2,377,991	1,361,101
Gross profit	1,254,253	466,467
Operating expenses:		
Sales and marketing	802,171	650,516
General and administrative	1,983,720	2,213,636
Operating expenses	2,785,891	2,864,152
Operating loss	(1,531,638)	(2,397,685)
Nonoperating income (expense):		
Interest income	469	295
Interest expense	(6,865)	(7,522)
Nonoperating expenses	(6,396)	(7,227)
Net loss	\$ (1,538,034)	\$ (2,404,912)
Basic and Diluted loss per common share	\$ (0.02)	\$ (0.03)
Basic and Diluted weighted average common shares outstanding	92,364,418	70,625,913

Quantitative Reconciliation of the differences between the non-GAAP measure and the associated comparable GAAP measure

Condensed Consolidated Statements of Operations (Unaudited, US GAAP) For the Three Month Periods Ended September 29, 2012 and October 1, 2011	Effects of Non-cash Charges associated with Share-based Compensation Expense For the Three Month Periods Ended September 29, 2012 and October 1, 2011		Condensed Consolidated Statements of Operations Excluding Share-based Compensation (Non-GAAP Presentation) For the Three Month Periods Ended September 29, 2012 and October 1, 2011		
	September 29, 2012	October 1, 2011			
Sales	\$ 3,632,244	\$ 1,827,568	Sales	\$ 3,632,244	\$ 1,827,568
Cost of sales	2,377,991	1,361,101	Cost of sales	2,377,991	1,361,101
Gross profit	1,254,253	466,467	Gross profit	1,254,253	466,467
Operating expenses:			Operating expenses:		
Sales and marketing	802,171	650,516	Sales and marketing	802,171	650,516
General and administrative	1,983,720	2,213,636	General and administrative	1,058,327	1,249,532
Operating expenses	2,785,891	2,864,152	Operating expenses	1,860,498	1,900,048
Operating loss	(1,531,638)	(2,397,685)	Operating loss	(606,245)	(1,433,581)
Nonoperating income (expense):			Nonoperating income (expense):		
Interest income	469	295	Interest income	469	295
Interest expense	(6,865)	(7,522)	Interest expense	(6,865)	(7,522)
Nonoperating expense	(6,396)	(7,227)	Nonoperating expense	(6,396)	(7,227)

Net loss	<u>\$ (1,538,034)</u>	<u>\$ (2,404,912)</u>	Net income	<u>\$ 925,393</u>	<u>\$ 964,104</u>	Net loss	<u>\$ (612,641)</u>	<u>\$ (1,440,808)</u>
Basic and Diluted loss per common share	<u>\$ (0.02)</u>	<u>\$ (0.03)</u>	Basic and Diluted income per common share	<u>\$ 0.01</u>	<u>\$ 0.01</u>	Basic and Diluted loss per common share	<u>\$ (0.01)</u>	<u>\$ (0.02)</u>
Basic and Diluted weighted average common shares outstanding	<u>92,364,418</u>	<u>70,625,913</u>	Basic and Diluted weighted average common shares outstanding	<u>92,364,418</u>	<u>70,625,913</u>	Basic and Diluted weighted average common shares outstanding	<u>92,364,418</u>	<u>70,625,913</u>

SOURCE ChromaDex Corporation